Literature DB >> 15334623

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine.

Anima Ghosal1, Yuan Yuan, Neil Hapangama, Ai Duen Iris Su, Narciso Alvarez, Swapan K Chowdhury, Kevin B Alton, James E Patrick, Shmuel Zbaida.   

Abstract

Desloratadine is a non-sedating antihistamine recently approved for the treatment of seasonal allergic rhinitis. The major metabolite of desloratadine in human plasma and urine is the glucuronide conjugate of 3-hydroxydesloratadine. 3-Hydroxydesloratadine-glucuronide is also the major in vitro metabolite of 3-hydroxydesloratadine formed by incubation of 3-hydroxydesloratadine with human liver microsomes supplemented with uridine 5'-diphosphate-glucuronic acid (UDPGA). The metabolite structure was confirmed by LC-MS and LC-MS/MS. Out of ten recombinant human UDP-glucuronosyltransferases (UGTs), UGT1A1, UGT1A3, UGT1A8 and UGT2B15 exhibited catalytic activity with respect to the formation of 3-hydroxydesloratadine-glucuronide. Inhibition studies with known inhibitors of UGT (diclofenac, flunitrazepam and bilirubin) confirmed the involvement of UGT1A1, UGT1A3 and UGT2B15 in the formation of 3-hydroxydesloratadine-glucuronide. The results from this study demonstrated that the in vitro formation of 3-hydroxydesloratadine-glucuronide from 3-hydroxydesloratadine was mediated via UGT1A1, UGT1A3 and UGT2B15 in human liver.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334623     DOI: 10.1002/bdd.405

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  3 in total

1.  Pharmacokinetics of desloratadine in children between 2 and 11 years of age.

Authors:  Samir Gupta; Sauzanne Khalilieh; Bhavna Kantesaria; Christopher Banfield
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Quantification of desloratadine in human plasma by LC-ESI-MS/MS and application to a pharmacokinetic study.

Authors:  Venkata Suresh Ponnuru; B R Challa; Ramarao Nadendla
Journal:  J Pharm Anal       Date:  2012-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.